MDT

95.91

-0.24%↓

136.91

+0.53%↑

VEEV

220.02

-1.38%↓

HQY

91.68

+0.19%↑

PHR.US

16.39

-3.02%↓

MDT

95.91

-0.24%↓

136.91

+0.53%↑

VEEV

220.02

-1.38%↓

HQY

91.68

+0.19%↑

PHR.US

16.39

-3.02%↓

MDT

95.91

-0.24%↓

136.91

+0.53%↑

VEEV

220.02

-1.38%↓

HQY

91.68

+0.19%↑

PHR.US

16.39

-3.02%↓

MDT

95.91

-0.24%↓

136.91

+0.53%↑

VEEV

220.02

-1.38%↓

HQY

91.68

+0.19%↑

PHR.US

16.39

-3.02%↓

MDT

95.91

-0.24%↓

136.91

+0.53%↑

VEEV

220.02

-1.38%↓

HQY

91.68

+0.19%↑

PHR.US

16.39

-3.02%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Open

SectorHealthcare

0.97

Buy Sell

Overview

Share price change

24h

Current

Min

0.96

Max

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+410.2% upside

Market Stats
By TradingEconomics
Market Cap	-11M 115M
Previous open	0.97
Previous close	0.97

News Sentiment

By Acuity

50%

141 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 gru 2025, 22:20 UTC

Major Market Movers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 gru 2025, 17:31 UTC

Major Market Movers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 gru 2025, 16:30 UTC

Major Market Movers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 gru 2025, 15:19 UTC

Major Market Movers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 gru 2025, 15:17 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 gru 2025, 14:37 UTC

Major Market Movers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1 sty 2026, 23:35 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

1 sty 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1 sty 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Sold Stake in JV to Tata Steel

1 sty 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 sty 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 gru 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 gru 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 gru 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 gru 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 gru 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 gru 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 gru 2025, 17:16 UTC

Major Market Movers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 gru 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 gru 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 gru 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 gru 2025, 15:02 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 gru 2025, 14:40 UTC

Acquisitions, Mergers, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 gru 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 gru 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

410.2% upside

12 Months Forecast

Average 5 USD 410.2%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

141 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.